Sustained Or Differential Release Type Patents (Class 424/468)
  • Patent number: 10645923
    Abstract: An insect bait that can be carried by the insect, that includes a toxicant capable of killing insects in a nest, and that includes attractants, having at least one non-toxic layer that delays contact with the toxicant, wherein the size, shape and attractants attract the insect to take the whole of the bait to a nest situation where further manipulation of the bait by the insect will release the toxicant.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: May 12, 2020
    Inventor: Carina Hiley
  • Patent number: 10583146
    Abstract: The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereon in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical compositions and kits are prepared in such a way that a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours. The invention also relates to a method for treating diseases requiring glucocorticoid treatment such as in subjects having a glucocorticoid deficiency disorder.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: March 10, 2020
    Assignee: SHIRE VIROPHARMA INCORPORATED
    Inventors: Stanko Skrtic, Jörgen Johnsson, Hans Lennernäs, Thomas Hedner, Gudmundur Johannsson
  • Patent number: 10561602
    Abstract: A controlled extended release composition comprising at least one unit dosage form having at least one active pharmaceutical ingredient (API), wherein said at least one API comprises at least one of pregabalin, a base thereof, a pharmaceutically acceptable prodrug thereof, a pharmaceutically acceptable derivative thereof, a pharmaceutically acceptable complex thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable polymorph thereof, a pharmaceutically acceptable hydrate thereof, a pharmaceutically acceptable solvate thereof, an enantiomer thereof and a racemate thereof. Methods and uses of the composition are provided.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: February 18, 2020
    Inventor: Isa Odidi
  • Patent number: 10537530
    Abstract: The invention provides a gastric resistant, enteric-coated solid dosage form including a core containing a pharmaceutically active ingredient, an inner coating for the core, and an outer enteric coating. The inner coating comprises an anionic polymeric material or a water-soluble neutral polymeric material, and further comprises a water soluble inorganic salt which is not a carbonate or bicarbonates. The outer enteric coating comprises an anionic polymeric material which is less neutralized than the polymeric material comprising the inner coating and disintegrates rapidly at a pH of 5.5 to 7.0 upon entering the small intestine.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: January 21, 2020
    Assignee: Evonik Operations GmbH
    Inventors: Fang Liu, Abdul W. Basit, Rosario Lizio, Hans-Ulrich Petereit, Christian Meier, Michael Damm
  • Patent number: 10537526
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: January 21, 2020
    Assignee: Purdue Pharma L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Patent number: 10534895
    Abstract: A computer system, computer program product and method for determining a probability of attaining a PK-PD target associated with efficacy for a patient that includes a processor obtaining information identifying an infection and based on the information, generating and displaying, by the processor, a list comprising one or more pathogens consistent with the information, the processor then obtaining a first indication designating at least one pathogen from the list comprising one or more pathogens and based on at the obtaining of the least one pathogen, generating a list comprising one or more drug therapies utilized to treat the at least one pathogen.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: January 14, 2020
    Assignee: ICPD Technologies, LLC
    Inventors: Paul G. Ambrose, Sujata Bhavnani, Christopher M. Rubino
  • Patent number: 10517840
    Abstract: A method for temporarily relieving sinus congestion and pressure comprising administering to a human a dose of a multi-particle pulsatile oral dosage form with an immediate release form and a plurality of delayed release particles. The immediate release form contains about 10 mg phenylephrine hydrochloride. The delayed release form contains a core with coatings including a phenylephrine coating containing about 10 mg phenylephrine hydrochloride and a pH sensitive coating.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: December 31, 2019
    Assignee: The Procter & Gamble Company
    Inventors: Richard John Dansereau, Daren Anness, Guhan Balan, David Ramsey
  • Patent number: 10507205
    Abstract: The present invention relates to the use of an inseparable combination of morphine and at least one opiate antagonist with a bioavailability of less than 5% on oral administration for producing a medicament to be administered orally for treatment of opiate dependency in humans and to the use of an inseparable combination of an opiate and at least one opiate antagonists with a bioavailability of less than 5% on oral administration for producing a medicament to be administered orally for prevention of non-oral opiate abuse in opiate addicts.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: December 17, 2019
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventor: Lars Hermann
  • Patent number: 10471025
    Abstract: The present invention relates to methods of treating and managing Parkinson's disease and related disorders. The methods especially find use in managing motor symptoms, including gait problems, particularly during advanced stages when effectiveness of standard medications wear off or side effects become problematic, as seen in Parkinson's disease, other disorders treated with dopaminergic agents, and other conditions associated with motor problems, such as aging or stroke. The treatment also may include disease-modifying effects, neuroprotection of, or neurorescue effects on neuronal cells in patients with Parkinson's disease and other neurodegenerative disorders.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: November 12, 2019
    Inventors: Nuno Afonso, Sara Sousa, Rita Vaz, Diana Chapela, Sofia Côrte-Real
  • Patent number: 10463622
    Abstract: Disclosed herein are treatments for diseases such as hypertension, diabetes, and congestive heart failure using controlled-release (CR, e.g., extended-release (ER) or prolonged-release (PR)) oral dosage formulations comprising an effective amount of Torsemide.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: November 5, 2019
    Inventor: Salim Shah
  • Patent number: 10449158
    Abstract: The invention provides a pharmaceutical composition comprising activated carbon particles, for oral administration. The pharmaceutical composition may be for (use in) the treatment of gastrointestinal fistula.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: October 22, 2019
    Assignee: FERRING B.V.
    Inventor: Soren Halskov
  • Patent number: 10449195
    Abstract: The present invention belongs to the pharmaceutical field, and in particular, it relates to a pharmaceutical formulation of palbociclib and a preparation method thereof. The pharmaceutical formulation comprises palbociclib, an acidic auxiliary material, and optionally a hydrophilic high-molecular weight material, which has better solubility and in vitro dissolution property as compared with the conventional formulation and can be used for enhancing in vivo absorption and bioavailability of palbociclib.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: October 22, 2019
    Assignee: SHENZHEN PHARMACIN CO., LTD.
    Inventors: Zeren Wang, Jun Xu, Long Qu
  • Patent number: 10441547
    Abstract: The present invention relates to co-extruded pharmaceutical compositions and dosage forms including an active agent, such as an opioid agonist, and an adverse agent, such as an opioid antagonist. Such compositions and dosage forms are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods of treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: October 15, 2019
    Assignee: PURDUE PHARMA L.P.
    Inventors: Robert P. Flath, John K. Masselink
  • Patent number: 10441605
    Abstract: The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a colon release coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: October 15, 2019
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Nils Ove Gustafsson, Nils-Olof Lindberg, Jessica Elversson
  • Patent number: 10441544
    Abstract: The invention provides an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: October 15, 2019
    Assignee: Douglas Pharmaceuticals, Ltd.
    Inventors: Paul William Glue, Natalie June Medlicott, Peter William Surman
  • Patent number: 10441604
    Abstract: The invention relates to small cholestyramine pellets that can be prepared by extrusion. The pellets have a high cholestyramine loading and are stable enough to be coated with one or more coating layers. The invention also relates to a process for the preparation of such pellets and to a multiparticulate drug delivery system comprising such pellets.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: October 15, 2019
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Nils Ove Gustafsson, Nils-Olof Lindberg, Jessica Elversson
  • Patent number: 10413526
    Abstract: A pharmaceutical composition or dietary supplement effective in the treatment of neuropathies and/or neuropathic pain is described, which comprises, as the active ingredients, the combination of curcumin, N-acetyl-L-carnitine and alpha-lipoic acid, wherein N-acetyl-L-carnitine and alpha-lipoic acid are present in the composition in the form of coated particles.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: September 17, 2019
    Assignee: Kolinpharma S.p.A.
    Inventors: Emanuele Lusenti, Ritapaola Petrelli
  • Patent number: 10398712
    Abstract: Provided are compositions and methods for treating multiple sclerosis (MS). One embodiment of the disclosed method entails orally administering to a MS patient a first amount of aspirin and a second amount of fumaric acid or an ester or a salt thereof. In some embodiments, the aspirin is administered at from about 80 mg to about 500 mg per day and the fumaric acid or ester or salt thereof is administered at about 360 mg per day.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: September 3, 2019
    Assignee: Vitalis LLC
    Inventor: Joseph Habboushe
  • Patent number: 10383862
    Abstract: The instant invention relates to a process for the preparation of a pharmaceutical composition in sustained-release tablet form comprising from 600 milligrams to 2400 milligrams of Pirfenidone (PFD), in such a way that the drug is bioavailable during an extended period of time of 12 hours from its administration. In this way, the anti-fibrotic and anti-inflammatory action of the drug Pirfenidone is optimized. Moreover, the instant invention offers advantages and a higher therapeutic efficacy compared to other pharmaceutical forms of Pirfenidone for oral administration and its therapeutic application in the regression of chronic renal failure secondary to primary glomerulosclerosis; it shows a better activity with regard to the reduction and/or regression of deleterious effects in breast capsular contracture observed after the surgical implantation of breast implants in humans and has an important anti-TNF-? and anti-TGF-?1 action for the treatment of hepatic fibrosis.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: August 20, 2019
    Assignee: CELL THERAPY AND TECHNOLOGY S.A. DE C.V.
    Inventors: Juan Socorro Armendáriz Borunda, José Agustin Rogelio Magaña Castro, Jorge Cervantes Guadarrama
  • Patent number: 10357496
    Abstract: Disclosed are methods for rapidly repleting folate levels of a woman for whom there is reason to believe that she may be pregnant or of a woman who believes that she may soon become pregnant. One of the methods includes administering to the woman two or more repletion doses of folate, wherein each of the repletion doses comprises no less than about 2.5 micromole of folate, wherein the repletion doses are administered no more than about one day apart, and wherein the total number of repletion doses administered to the woman is 72 or fewer.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: July 23, 2019
    Assignee: South Alabama Medical Science Foundation
    Inventors: Steven W. Bailey, June E. Ayling
  • Patent number: 10357479
    Abstract: A method is described for the treatment of systemic diseases in cats. A composition is administered to a cat, where the composition includes a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan).
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: July 23, 2019
    Assignee: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Marcus Stark, Ulrike D. Sent, Ingo Lang
  • Patent number: 10350212
    Abstract: Disclosed herein are methods, pharmaceutical combinations, or kits for the prevention or treatment of extrapyramidal syndromes, for example, dyskinesia, dystonia, akathisia, or drug-induced Parkinsonism, with the administration of a therapeutic effective amount of Trapidil, a derivative, a metabolite, a prodrug, an analog, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: July 16, 2019
    Assignee: SINOPIA BIOSCIENCES, INC.
    Inventor: Aarash Bordbar
  • Patent number: 10343184
    Abstract: Provided is a drug-eluting coronary stent. In the drug-eluting coronary stent according to the present invention, electrospinning is used, thereby making it possible to precisely control a total content of an everolimus-based drug bound thereto and form a uniform layer in spite of not using a polymer causing late thrombosis, or the like.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: July 9, 2019
    Assignee: CHONNAM NATIONAL UNIVERSITY HOSPITAL
    Inventors: Dae Sung Park, In-Ho Bae, Jae Won Shim, So Youn Lee, Eun Jae Jang, Kyung Seob Lim, Jun Kyu Park, In Soo Kim, Doo Sun Sim, Myung Ho Jeong
  • Patent number: 10336058
    Abstract: The invention provides for the use of pharmaceutical compositions comprising a thiazolide in the stimulation of the immune system in a subject in need thereof, thereby preventing and/or treating viral diseases, cancer and diseases caused by intracellular protozoan infections.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: July 2, 2019
    Assignee: ROMARK LABORATORIES L.C.
    Inventor: Jean-Francois Rossignol
  • Patent number: 10307416
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: June 4, 2019
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • Patent number: 10300141
    Abstract: A pharmaceutical dosage form exhibiting a breaking strength of at least 500 N, wherein the dosage form contains a pharmacologically active ingredient (A); an inorganic salt (B); and a polyalkylene oxide (C) having a weight average molecular weight of at least 200,000 g/mol, wherein the content of the polyalkylene oxide (C) is at least 20 wt.-%, based on the total weight of the dosage form; wherein the pharmacologically active ingredient (A) is present in a controlled-release matrix comprising the inorganic salt (B) and the polyalkylene oxide (C) and wherein, under in vitro conditions, the release profile of the pharmacologically active ingredient (A) from the matrix comprises at least a time interval during which the release follows zero order kinetics.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: May 28, 2019
    Assignee: GRÜNENTHAL GMBH
    Inventor: Lutz Barnscheid
  • Patent number: 10272062
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: April 30, 2019
    Assignee: Flamel Ireland Limited
    Inventors: Claire Mégret, Hervé Guillard, Jean-François Dubuisson
  • Patent number: 10238684
    Abstract: The present invention relates to a dietary supplement, composition, nutraceutical, and/or system for inducing or treating biological responses or conditions (namely sleep or sleep disorders) which utilize ultra-low dosage amounts of vitamins, minerals, amino acids, co-enzymes, stimulants, and/or similar ingredients in a highly bio-active delivery system which bypasses first pass metabolism. In particular, the present invention relates to a nutraceutical composition/formulation which substantially bypasses first pass metabolism and such as, but not limited to, activation of the glymphatic system to facilitate clearance of neuronal metabolites from the CSF and interstitial fluids in the brain.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: March 26, 2019
    Assignee: Foundational BioSystems, LLC
    Inventor: Jon Scott Theus
  • Patent number: 10231978
    Abstract: The present invention provides methods and compositions for treating cancer, reducing side effects, and reducing postmenopausal symptoms comprising anordrin or analog thereof (such as anordrin) alone or in combination with at least one other agent selected from the group consisting of tamoxifen, raloxifene or functional equivalent thereof, and an aromatase inhibitor.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: March 19, 2019
    Assignees: SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH, CHANGZHOU RUIMING PHARMACEUTICAL COMPANY, LTD.
    Inventors: Jun Yang, Huijuan Shi, Wenping Xu
  • Patent number: 10206881
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: February 19, 2019
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Patent number: 10166194
    Abstract: The disclosure relates to a pharmaceutical formulation comprising hydrocortisone and its use in the treatment of conditions that would benefit from a delayed release of hydrocortisone, in particular conditions such as adrenal insufficiency, inflammatory conditions and depression.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: January 1, 2019
    Assignee: Diurnal Limited
    Inventors: Hiep Huatan, Richard Ross, Martin Whitaker
  • Patent number: 10154966
    Abstract: The invention relates to a tamper-resistant pharmaceutical dosage form comprising one or more particles, wherein each of said one or more particles comprises a pharmacologically active ingredient and a physiologically acceptable polymer; has a breaking strength of at least 300 N; has a weight of at least 2 mg; and optionally, comprises a film-coating; wherein the total weight of the pharmaceutical dosage form is greater than the total weight of said one or more particles.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: December 18, 2018
    Assignee: GRÜNENTHAL GMBH
    Inventors: Lutz Barnscheid, Anja Geiβler, Klaus Wening, Jana Pätz
  • Patent number: 10143755
    Abstract: The present disclosure relates to anhydrous hydrogels useful as mucoadhesive (oral compositions) or as topical agents and may be used to deliver an active agent such as active pharmaceutical agents (API's), coagulants, fragrances, flavors, and other actives and excipients.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: December 4, 2018
    Assignee: Acupac Packaging Inc.
    Inventors: John Borja, Stephanie Sharon Hayano
  • Patent number: 10143698
    Abstract: The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: December 4, 2018
    Assignee: COSMO TECHNOLOGIES LIMITED
    Inventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
  • Patent number: 10143654
    Abstract: Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: December 4, 2018
    Assignee: Physician's Seal, LLC
    Inventors: Syed M. Shah, Daniel Hassan, Christopher Diorio, Fred Hassan
  • Patent number: 10105330
    Abstract: Compositions for reducing the frequency of urination and methods of manufacturing the compositions are disclosed. The compositions comprises a first component having an immediate-release subcomponent and an extended-release subcomponent, wherein the first component is formulated to release the subcomponents immediately after administration; and a second component comprising an immediate-release subcomponent and an extended-release subcomponent, wherein the second component is formulated for a delayed-release of the subcomponents.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: October 23, 2018
    Assignee: WELLESLEY PHARMACEUTICALS, LLC
    Inventor: David A. Dill
  • Patent number: 10105374
    Abstract: The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: October 23, 2018
    Assignee: COSMO TECHNOLOGIES LIMITED
    Inventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
  • Patent number: 10105328
    Abstract: Pharmaceutical compositions for reducing frequency of urination are disclosed. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier. Also disclosed are methods of making and using the pharmaceutical compositions.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: October 23, 2018
    Assignee: WELLESLEY PHARMACEUTICALS, LLC
    Inventor: David A. Dill
  • Patent number: 10098571
    Abstract: Disclosed is a digestive tract patency capsule, comprising an outer membrane (2) and a supporting material (1) which is soluble in digestive juices. The outer membrane (2) is a sealed soft capsule body made from a sustained-release enteric material, and the dissolution time of the outer membrane (2) is greater than the normal emptying time of the human digestive tract. The cavity of the capsule body of the outer membrane (2) is provided with an indicator (5) which can be absorbed by the body and enables the discharged urine to change color. The supporting material (1) is provided in the cavity of the capsule body of the outer membrane (2) to support the outer membrane (2) in a capsule form. The digestive tract patency capsule can safely and effectively check the feasibility of performing a capsule endoscopic examination on a user.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: October 16, 2018
    Inventor: Side Liu
  • Patent number: 10092531
    Abstract: Valproate is useful as an antifungal agent. The valproate compositions can be used to treat fungal infections. The valproate compositions can be formulated as topical antifungals.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: October 9, 2018
    Assignee: Wayne State University
    Inventors: Miriam L. Greenberg, Rania M. Deranieh
  • Patent number: 10064856
    Abstract: Methods and compositions are provided which comprise effective amounts of an analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: September 4, 2018
    Assignee: LOCAL PHARMA, INC.
    Inventors: Paul Bosse, John Ameling, Bernard Schachtel, Ray Takigiku
  • Patent number: 10065981
    Abstract: The present invention provides sialic acid analogs and their compositions useful for the treatment of sialic acid deficiencies.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: September 4, 2018
    Assignee: Ultragenyx Pharmaceutical Inc.
    Inventors: Emil Kakkis, Steven Jungles, He Zhao
  • Patent number: 10064878
    Abstract: The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: September 4, 2018
    Assignee: COSMO TECHNOLOGIES LTD.
    Inventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
  • Patent number: 10052316
    Abstract: The present invention relates to compositions and methods for prophylactic and/or therapeutic treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more compounds selected from the group consisting of epicatechin, an epicatechin derivative, catechin, a catechin derivative, nicorandil, and a nicorandil derivative in an amount effective to ameliorate mitochondrial toxicity caused by administration of a chemical, food, or drug.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: August 21, 2018
    Assignee: Cardero Therapeutics, Inc.
    Inventors: Francisco Villarreal, Alan Maisel, George Schreiner, Guillermo M. Ceballos Reyes, Pam Taub
  • Patent number: 10052286
    Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: August 21, 2018
    Assignee: COSMO TECHNOLOGIES LIMITED
    Inventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
  • Patent number: 10028996
    Abstract: A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogs, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred, without heat detection, at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: July 24, 2018
    Assignee: Thorn BioScience LLC
    Inventor: James W. Lauderdale
  • Patent number: 9999599
    Abstract: The invention provides novel nanoscale delivery vehicles and composite nanoassemblies built from distinct nanoassembly units (e.g., block copolymer micelles and nanogels) with stoichiometric control. These intelligent composite nanoassemblies independently retain the key features of the nanoassembly units and greatly expand the potential functional features attainable based on the surface functionalization. The invention provides a novel approach to constructing nano-vehicles with controllable morphology based on combination of cooperative releasing mechanisms (e.g., redox sensitive nanogels and pH sensitive micelles). Two kinds of guests can be seperately and stably encapsulated in the composite nanocontainers, and then released sequentially under the stimulation of pH change and reduced glutathione.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: June 19, 2018
    Assignee: University of Massachusetts
    Inventors: Sankaran Thayumanavan, Conghui Yuan
  • Patent number: 9987364
    Abstract: A water-swellable linear polyurethane polymer is formed by reacting a polyethylene oxide (e.g. PEG 4000 to 35,000), a difunctional compound (e.g. a diamine or diol such as 1,10-decanediol) with a diisocyanate. The ratio of the three components is generally in the range 0.1-1.5 to 1 to 1.1-2.5. The polyurethane is water-swellable in the range 300 to 1700% and soluble in certain organic solvents such as dichloromethane. It can be loaded with pharmaceutically active agents, particularly of high molecular weight, to produce controlled release compositions, such as pessaries etc.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: June 5, 2018
    Assignee: Ferring B.V.
    Inventors: Janet Anne Halliday, Jukka Tuominen, Mark Alexander Livingstone, Frank Koppenhagen, Lilias Morton Currie, Sarah Stewart
  • Patent number: 9981979
    Abstract: There is provided a novel process for the preparation of a hydrocodone salt. In particular, there is provided a novel process for the preparation of a free-flowing slurry of a hydrocodone salt, for example, a free-flowing slurry of hydrocodone bitartrate hemipentahydrate.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: May 29, 2018
    Assignee: Cambrex Charles City, Inc.
    Inventors: Michael Robert Tracey, Zhiming Eric Dong
  • Patent number: 9976171
    Abstract: The invention is directed to a process for measuring the amount of digestive enzymes released from a solid composition in a dissolution medium by fluorescence spectroscopy. The invention is also directed to a combined method for measuring both the dissolution and gastroresistance of a solid compositions comprising pancrelipase.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: May 22, 2018
    Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
    Inventors: Massimo Latino, Luigi Ghidorsi, Giovanni Ortenzi